Allergan to Sell Corneal Ulcer Drug
- Share via
IRVINE — Allergan Inc. said it has received approval from the Food and Drug Administration to market Ocuflox 0.3% for the treatment of corneal ulcers. Allergan said the ophthalmic solution is already indicated for the treatment of bacterial conjunctivitis.
The company, which develops, manufactures and markets specialty therapeutic products for eye and skin care and neuromuscular disorders, licenses Ocuflox from Daiichi Pharmaceutical Co., in Tokyo, and Santen Pharmaceutical Co., in Osaka, Japan.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
